Literature DB >> 8816498

Destabilization of Raf-1 by geldanamycin leads to disruption of the Raf-1-MEK-mitogen-activated protein kinase signalling pathway.

T W Schulte1, M V Blagosklonny, L Romanova, J F Mushinski, B P Monia, J F Johnston, P Nguyen, J Trepel, L M Neckers.   

Abstract

The serine/threonine kinase Raf-1 functions downstream of Rats in a signal transduction cascade which transmits mitogenic stimuli from the plasma membrane to the nucleus. Raf-1 integrates signals coming from extracellular factors and, in turn, activates its substrate, MEK kinase. MEK activates mitogen-activated protein kinase (MAPK), which phosphorylates other kinases as well as transcription factors. Raf-1 exists in a complex with HSP90 and other proteins. The benzoquinone ansamycin geldanamycin (GA) binds to HSP90 and disrupts the Raf-1-HSP90 multimolecular complex, leading to destabilization of Raf-1. In this study, we examined whether Raf-1 destabilization is sufficient to block the Raf-1-MEK-MAPK signalling pathway and whether GA specifically inactivates the Raf-1 component of this pathway. Using the model system of NIH 3T3 cells stimulated with phorbol 12-myristate 13-acetate (PMA), we show that GA does not affect the ability of protein kinase C alpha to be activated by phorbol esters, but it does block activation of MEK and MAPK. Further, GA does not decrease the activity of constitutively active MEK in transiently transfected cells. Finally, disruption of the Raf-1-MEK-MAPK signalling pathway by GA prevents both the PMA-induced proliferative response and PMA-induced activation of a MAPK-sensitive nuclear transcription factor. Thus, we demonstrate that interaction between HSP90 and Raf-1 is a sine qua non for Raf stability and function as a signal transducer and that the effects observed cannot be attributed to a general impairment of protein kinase function.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8816498      PMCID: PMC231585          DOI: 10.1128/MCB.16.10.5839

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  54 in total

Review 1.  Lipid activation of protein kinase C.

Authors:  R M Bell; D J Burns
Journal:  J Biol Chem       Date:  1991-03-15       Impact factor: 5.157

Review 2.  The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation.

Authors:  P Angel; M Karin
Journal:  Biochim Biophys Acta       Date:  1991-12-10

3.  Insulin-stimulated MAP-2 kinase phosphorylates and activates ribosomal protein S6 kinase II.

Authors:  T W Sturgill; L B Ray; E Erikson; J L Maller
Journal:  Nature       Date:  1988-08-25       Impact factor: 49.962

4.  Mitogen-activated Swiss mouse 3T3 RSK kinases I and II are related to pp44mpk from sea star oocytes and participate in the regulation of pp90rsk activity.

Authors:  J Chung; S L Pelech; J Blenis
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-01       Impact factor: 11.205

5.  Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms.

Authors:  M Y Chiang; H Chan; M A Zounes; S M Freier; W F Lima; C F Bennett
Journal:  J Biol Chem       Date:  1991-09-25       Impact factor: 5.157

6.  Protein kinase C is required for responses to T cell receptor ligands but not to interleukin-2 in T cells.

Authors:  V E Valge; J G Wong; B M Datlof; A J Sinskey; A Rao
Journal:  Cell       Date:  1988-10-07       Impact factor: 41.582

7.  Phosphorylation of c-jun mediated by MAP kinases.

Authors:  B J Pulverer; J M Kyriakis; J Avruch; E Nikolakaki; J R Woodgett
Journal:  Nature       Date:  1991-10-17       Impact factor: 49.962

8.  A phosphorylation site located in the NH2-terminal domain of c-Myc increases transactivation of gene expression.

Authors:  A Seth; E Alvarez; S Gupta; R J Davis
Journal:  J Biol Chem       Date:  1991-12-15       Impact factor: 5.157

9.  Raf-1 protein kinase is required for growth of induced NIH/3T3 cells.

Authors:  W Kolch; G Heidecker; P Lloyd; U R Rapp
Journal:  Nature       Date:  1991-01-31       Impact factor: 49.962

10.  The AP-1 site at -150 bp, but not the NF-kappa B site, is likely to represent the major target of protein kinase C in the interleukin 2 promoter.

Authors:  J Jain; V E Valge-Archer; A J Sinskey; A Rao
Journal:  J Exp Med       Date:  1992-03-01       Impact factor: 14.307

View more
  56 in total

Review 1.  Geldanamycin: the prototype of a class of antitumor drugs targeting the heat shock protein 90 family of molecular chaperones.

Authors:  H J Ochel; K Eichhorn; G Gademann
Journal:  Cell Stress Chaperones       Date:  2001-04       Impact factor: 3.667

2.  Non-transcriptional action of oestradiol and progestin triggers DNA synthesis.

Authors:  G Castoria; M V Barone; M Di Domenico; A Bilancio; D Ametrano; A Migliaccio; F Auricchio
Journal:  EMBO J       Date:  1999-05-04       Impact factor: 11.598

3.  KRIBB11 inhibits HSP70 synthesis through inhibition of heat shock factor 1 function by impairing the recruitment of positive transcription elongation factor b to the hsp70 promoter.

Authors:  Young Ju Yoon; Joo Ae Kim; Ki Deok Shin; Dae-Seop Shin; Young Min Han; Yu Jin Lee; Jin Soo Lee; Byoung-Mog Kwon; Dong Cho Han
Journal:  J Biol Chem       Date:  2010-11-15       Impact factor: 5.157

4.  The Hsp90-specific inhibitor geldanamycin selectively disrupts kinase-mediated signaling events of T-lymphocyte activation.

Authors:  T Schnaider; J Somogyi; P Csermely; M Szamel
Journal:  Cell Stress Chaperones       Date:  2000-01       Impact factor: 3.667

5.  AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer.

Authors:  Jose V Moyano; Joseph R Evans; Feng Chen; Meiling Lu; Michael E Werner; Fruma Yehiely; Leslie K Diaz; Dmitry Turbin; Gamze Karaca; Elizabeth Wiley; Torsten O Nielsen; Charles M Perou; Vincent L Cryns
Journal:  J Clin Invest       Date:  2006-01       Impact factor: 14.808

Review 6.  Functions of the Hsp90 chaperone system: lifting client proteins to new heights.

Authors:  Julia M Eckl; Klaus Richter
Journal:  Int J Biochem Mol Biol       Date:  2013-12-15

7.  The HSP90 inhibitor ganetespib synergizes with the MET kinase inhibitor crizotinib in both crizotinib-sensitive and -resistant MET-driven tumor models.

Authors:  Naoto Miyajima; Shinji Tsutsumi; Carole Sourbier; Kristin Beebe; Mehdi Mollapour; Candy Rivas; Soichiro Yoshida; Jane B Trepel; Ying Huang; Manabu Tatokoro; Nobuo Shinohara; Katsuya Nonomura; Len Neckers
Journal:  Cancer Res       Date:  2013-10-11       Impact factor: 12.701

Review 8.  The HSP90 chaperone machinery.

Authors:  Florian H Schopf; Maximilian M Biebl; Johannes Buchner
Journal:  Nat Rev Mol Cell Biol       Date:  2017-04-21       Impact factor: 94.444

9.  Designed Hsp90 heterodimers reveal an asymmetric ATPase-driven mechanism in vivo.

Authors:  Parul Mishra; Daniel N A Bolon
Journal:  Mol Cell       Date:  2014-01-23       Impact factor: 17.970

10.  Hsp90 as a gatekeeper of tumor angiogenesis: clinical promise and potential pitfalls.

Authors:  J E Bohonowych; U Gopal; J S Isaacs
Journal:  J Oncol       Date:  2010-06-24       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.